Background: The purpose of this study was to address the affects of mood modifying drugs on the transcriptome, in a tissue culture model, using qPCR arrays as a cost effective approach to identifying regulatory networks and pathways that might coordinate the cell response to a specific drug.
Introduction
Mental health is in part dependent upon transcriptional responses to cues which can be environmental, chemical, physiological and psychological; this is termed the Gene x Environment (GxE) component. These changes not only affect our health in the short term, but can have medium to long term impact via epigenetic modulation of gene expression, altering our response to environmental challenges. Genetic polymorphism can modulate the GxE response and offer insight into the mechanisms underpinning such pathways . Earlier genetic studies targeted association of one genetic variant to a specific disorder; this had limited success and focused predominantly on candidate genes such as those in the monoaminergic pathways. These correlations are now being readdressed by analysing multiple variants in such pathways or by stratification of the cohorts based on environmental factors. Our recent work on a promoter polymorphism of the monoamine oxidase A gene and maternal parameters affecting infant behaviour is an example of the latter (Hill et al., 2013) . It is difficult to address the signal cascade in response to specific challenges in vivo due to the heterogeneity of cells involved in processing the environmental signals mediating a cellular response. However, in vitro cell line models offer an opportunity to address in fine detail the signal pathways modulated in response to a specific challenge. In this study we analysed the response to distinct drugs in the human neuroblastoma cell line SH-SY5Y targeting a commercially available compilation of mood disorder genes to address whether they leave a molecular signature of transcriptional change to the challenge. The drugs chosen for comparison included two psychostimulant challenges, amphetamine and cocaine, and two mood stabilisers, sodium valproate and lithium. All of these drugs have been shown previously to modulate signal pathways in SH-SY5Y cells at the transcriptional and/or post-transcriptional level (Asghari et al., 1998; Di Daniel et al., 2005; Kantor et al., 2002; Lew, 1992; Pan et al., 2005; Warburton et al., 2014) . Our analysis identified similarities and differences in the networks modified by the drug challenge which suggested an overlap in the pathways of the mood stabilisers. These changes reflect one window for the spectrum of changes that could occur in vivo, but nonetheless outline the potential for a concerted cellular response to drug exposure.
Materials and methods

Cell culture and drug treatment
Human derived SH-SY5Y neuroblastoma cells (American Type Culture Collection) were maintained in Earle's modified Eagle's medium (EMEM) (Sigma) and HAM's F12 (Sigma) at a ratio of 1:1, supplemented with 10% foetal calf serum (FCS) (Sigma), 1% 200mM L-glutamine, 1% 100mM sodium pyruvate and 100 U/ml penicillin /100 ug/ml streptomycin at 37°C and 5% CO 2 . Amphetamine, cocaine hydrochloride, lithium chloride and valproic acid sodium salt were purchased from Sigma and stock solutions made using sterile filtered dH 2 O. Drug regimes were 1 hour treatment with either: vehicle control (sterile filtered dH 2 O), 10µM amphetamine (Jones and Kauer, 1999; Shyu et al., 2004) , 10µM cocaine (Warburton et al., 2014) , 1mM lithium (Hing et al., 2012; Roberts et al., 2007) or 5mM sodium valproate (Pan et al., 2005; Phiel et al., 2001; Zhang et al., 2003) . For each drug treatment, n=4. Basal (untreated) cells were also included.
RNA extraction and quantitative polymerase chain reaction (qPCR) analysis
Total RNA was extracted using Trizol reagent (Invitrogen) and the resulting RNA pellets resuspended in RNase-free water. 500ng RNA was reverse transcribed into cDNA using the GoScript TM the genes that showed minimal changes, which were defined on Ct values obtained using the Global Pattern Recognition analysis software (Akilesh et al., 2003) .
A list of genes on the mood array is given in Table 1 .
Bioinformatic analysis
Gene expression data generated from GPR analysis was uploaded into the online biological pathway analysis software MetaCore TM , version 6.15 build 62452. were included and the position of NRSF binding sites calculated. For genes with multiple transcripts, the locus for the largest isoform was used. The full list of NRSF binding sites are detailed in Table 3 .
Results
Gene expression profiling of human SH-SY5Y cells in response to mood-modifying drugs using
Global Pattern Recognition analysis
To investigate the effects of mood modifying drugs on the expression of a panel of genes associated with mood disorders (Human Mood Disorder 96 StellARray™), SH-SY5Y neuroblastoma cells after treatment for 1 hour under one of the specified conditions were analysed using the proprietary Global Pattern Recognition (GPR) algorithm which compares the change in expression of a gene normalised to the expression of every other gene in the array (Akilesh et al., 2003) . This software calculates both the fold-change data and the respective p-values with respect to genes that showed minimal changes.
We and others have recently demonstrated that drugs used in the treatment of mood disorders can differentially affect the expression stability of traditionally used housekeeping genes, impacting upon their usefulness as normalising factors (D'Souza et al., 2013; Powell et al., 2013; Sugden et al., 2010) . Unfortunately, these large changes in gene expression may mask small but biologically important changes in gene expression, such as master regulator genes (e.g., transcription factors).
The data in Table 2 therefore represents a more appropriate display of the genes most changed within the experiment by comparing all genes against themselves. As the array contains validated mood genes we addressed the top 10 genes which significantly changed in response to each drug to define pathways and networks within the larger gene list.
Following treatment with the mood stabiliser sodium valproate, 8 genes were significantly (p<0.05) upor down-regulated compared to the vehicle control; 2 up-regulated (JUN and PAFAH1B3) and 6 down-regulated (DRD3, GAD1, NRG1, PER3, RELN and RGS4). When compared to the results obtained after treatment with another common mood stabiliser, lithium, similarities in the gene expression profile with respect to the top 10 altered genes was observed; namely down-regulation of GAD1, NRG1, PER3, RELN and RGS4, but, only GAD1 reached statistical significance at this time point for lithium treatment. In addition, FOS was significantly down-regulated in response to lithium.
Treatment with the two psychomotor stimulants cocaine and amphetamine demonstrated no statistically significant changes in gene expression following 1 hour treatment. Furthermore the genes with the lowest p-values were distinct between the psychostimulants apart from MOBP (Table 2) demonstrating that these drugs might be preferentially targeting distinct pathways for their action.
However due to the low p-values obtained under these experimental conditions we did not pursue their analysis further.
Network analysis of genes significantly modulated in response to mood stabilisers
To further explore potential gene networks important in the response to drug challenge, we analysed only the genes whose expression was most affected by lithium and sodium valproate using the As our gene expression data showed that 7/9 of the significantly modulated genes were downregulated (Table 2) and NRSF which predominantly functions as a transcriptional repressor was identified as an important regulator of our gene set, we addressed predicted NRSF binding sites using To determine how these regulatory pathways were most relevant for mood disorders, we filtered our dataset using the MetaCore TM 'Filter by Disease' feature which traces all of the known associated interactions for a particular disease process. This assigned 46.15% of our network, not unexpectedly to disease processes relating to mood (Figure 2A ). Furthermore, it identified NRSF and ERK1/2 signalling along the oestrogen receptor pathway as important regulators of processes relevant to mood disorders involving this subset of genes. In addition to disorders of the CNS, filtering of our dataset by disease showed there to be significant associations (96.15%) with breast, skin and gastrointestinal neoplasia; GAD1 being the only gene not to be involved in these cancer-related pathologies ( Figure 2B ). To further assess which signalling pathways may be operating in response to challenge with these mood stabilisers, we also filtered our experimental network for Drug Responses under the Gene Ontology (GO) Processes filter. This identified the fibroblast growth factor, ERBB and neurotrophin TRK receptor signalling pathways as important cellular responses, with the dopamine D3 receptor, EGFR, ErbB2, ErbB3 and c-Src highlighted as therapeutic targets ( Figure 2C ).
Discussion
Understanding the mechanism of action for a drug to alter the cell phenotype, in addition to the initial cellular targets recognised by the drug, is important for both clinical application and pharmaceutical development. Transcriptome profiling allows for global scale interrogation of potential regulatory mechanisms involved in modulating cellular responses to a particular drug through the use of pathway analysis tools. The aim of this study was to address the effects of mood modifying drugs on the expression profile of a commercially available panel of genes associated with mood disorders by network analysis to compare and contrast their mode of action.
We used two mood stabilisers (lithium and sodium valproate) and two mood stimulants (cocaine and amphetamine). Only the mood stabilisers reached statistical significance and interestingly they shared 5 genes in their top 9 most modified genes, Table 2 ; we therefore focused on this set of genes for further analysis. Valproate significantly modified 8 genes, lithium only two, GAD1 and FOS, with GAD1 being significantly down-regulated for both drugs. GAD1 encodes one of several forms of glutamic acid decarboxylase which is a key enzyme for the synthesis of the inhibitory neurotransmitter GABA. GAD1 is implicated from both genetic and functional analysis as a modulator of mood (Domschke et al., 2013; Hettema et al., 2006; Karolewicz et al., 2010; Lundorf et al., 2005; Thompson et al., 2009; Weber et al., 2012) . FOS and JUN proteins constitute the AP-1 transcription factor complex which was a target for modulation. These factors represent a family of proteins that heterodimerise to regulate the AP-1 DNA site (Quinn, 1991; Quinn et al., 1989a; Quinn et al., 1989b; Takimoto et al., 1989) . Lithium and sodium valproate have both been demonstrated to modulate the AP-1 complex (Chen et al., 2008; Ozaki and Chuang, 2002) . The genes shared in common by the mood stabilisers sodium valproate and lithium were GAD1, NRG1, PER3, RELN and RGS4. The remainder, DRD3, JUN and PAFAH1B3 were specific for sodium valproate. Although some of these genes were modified with cocaine and amphetamine, the statistical significance was low, certainly lower than all the genes in the 9 most differentially expressed genes in Table 2 . We have previously used cocaine and amphetamine in SH-SY5Y and found that we can observe significant changes in genes involved in mental health. For example, recently in the approximate same passage number of cells as used in this experiment, we have demonstrated that cocaine altered the expression of the schizophrenia candidate gene MIR137 (Warburton et al., 2014) . However under the current experimental conditions this gene set targeting mood disorders is not responding as robustly to cocaine and amphetamine as lithium and sodium valproate. We therefore attempted to determine whether the significant mood stabiliser gene set defined a specific pathway or network of genes to explain their concerted response to drug exposure.
Pathway analysis using both the Analyse Networks (Transcription Factors) and Filter by Disease algorithms available on the online pathway analysis software MetaCore TM identified the transcription factor NRSF, also termed REST (repressor element-1 silencing transcription factor), to be strongly associated with the pathways supporting these networks of genes. NRSF has a direct association with DRD3, GAD1 and RELN genes based on the network analysis, Figure 1 . (Lu et al., 2014) . NRSF has the properties to modulate epigenetic factors in its target genes due to its association with a plethora of co-activators, such as members of the SWI/SNF family, which can modify histones by post-translational modifications (Loe-Mie et al., 2010) . These epigenetic modifications could result in medium to long term changes in gene expression that underlie drug exposure in addition to the immediate modulation of the transcriptome. Our data suggest that lithium and sodium valproate, with different initial cellular targets, may modulate related signalling pathways leading to overlapping cellular responses mediated in part by the NRSF pathway. It should be noted that we performed this experiment at 1 hour post exposure to capture an early response of the cell to the drug. As in any stimulus induction modification of gene expression many of these changes will be transient, especially in the short term for transcription factors such as AP-1 and NRSF. This is in keeping with the transient response of AP-1 and NRSF in stimulus inducible gene expression models we have previously observed at 1 hour post exposure (Gillies et al., 2009; Howard et al., 2008; Quinn, 1991; Spencer et al., 2006) . A more extensive timescale would perhaps have demonstrated a different or related set of genes, nevertheless, our strategy allowed the observation of the differential gene set acting as a signature for the mood stabilisers and allows for future optimisation.
Filtering our dataset by disease also identified ERK1/2 signalling along with the oestrogen receptor pathway as a potentially important regulatory network for this gene set ( Figure 2 ). Oestrogen receptor signalling has been well documented in the modulation of behaviours relating to aggression (Nomura et al., 2002) , anxiety and depression (Furuta et al., 2013) . The action of sex hormones may in part explain why in conditions such as panic disorder these phenotypes are more prevalent among females. Our data would be consistent with GAD1 SNP variation being tentatively associated for the higher susceptibility of females to panic disorder (Weber et al., 2012) via modulation by oestrogen.
This oestrogen pathway could overlap with other transcription factor pathways identified in our analysis, for example synergistic action of the oestrogen and AP-1 pathways on gene expression (Fujimoto and Kitamura, 2004) . The extended networks identified in this study (AP-1, oestrogen and NRSF) may also work synergistically, for example NRSF activity is important for E2 stimulation of the cell cycle (Bronson et al., 2010) and oestrogen receptor B is enriched at NRSF binding sites (Le et al., 2013) . Such interactions between these three pathways can be further modified by the glucocorticoid receptor, so linking these pathways to a major driver of mood (Abramovitz et al., 2008; Karmakar et al., 2013) . Glucocorticoid sensitivity is strongly associated with several mood related disorders (Spijker and van Rossum, 2012) and anti-glucocorticoid drugs have been used in the treatment of such conditions (Gallagher et al., 2008; Wolkowitz and Reus, 1999; Wolkowitz et al., 1999) . Mood disorder susceptibility has also been linked to glucocorticoid signalling through its modulation of the stress response along the hypothalamic-pituitary-adrenal (HPA) axis (Lupien et al., 2009; Spijker and van Rossum, 2012) .
Our data points to a cost effective and rapid assessment of expression changes in selected genes using GPR analysis, which can help delineate the pathways targeted by drugs to modify mood. In particular, we have identified dopamine and glutamine pathways as being important; perhaps not unexpectedly as the gene set is enriched for known genes involved in mood disorders. Alteration in the regulation of these pathways would be expected to modulate mood and is reflected in the range of drugs currently used in targeting these pathways. However the modulation of the AP-1 pathway and the involvement of factors such as NRSF and ERK1/2 highlight a more general modulation of neurotransmitter pathways in response to mood modifying drugs. Our model can therefore be used to determine mechanisms associated with off target and long term affects of particular drugs and can be extrapolated to predict in vivo responses, utilised in the comparison of multiple drug regimes or used as an initial screening process to inform optimal drug design.
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